BillionToOne, Inc.

BillionToOne, Inc. operates as a precision molecular diagnostics company specializing in non-invasive single-molecule next-generation sequencing tests. The organization develops liquid biopsy screening tools utilizing cell-free DNA to assess fetal genetic conditions and evaluate oncology therapy outcomes. Its prenatal portfolio includes the UNITY suite of maternal blood tests, which screen for recessive genetic conditions, chromosomal aneuploidies, microdeletions, and fetal red blood cell antigens. In oncology, the firm offers Northstar Select for solid tumor therapy guidance and Northstar Response for monitoring treatment efficacy and quantifying tumor burden. The company's primary customers include obstetricians, maternal-fetal medicine specialists, oncologists, healthcare systems, and clinical trial partners.

The business delivers its diagnostic screening services across the United States and has secured regulatory clearances for clinical trial testing in select European and Latin American jurisdictions. BillionToOne conducts prospective multi-site clinical evaluations across academic medical centers and healthcare networks, including over 150,000 completed fetal RhD assessments. The provided text does not identify the location of the company's headquarters.

Summary of the business section of BillionToOne's latest annual report, written by StockData.